Evidence mapPaperPMID 19590846Full record

ArticleDiabetologia2009

Pathophysiology and aetiology of impaired fasting glycaemia and impaired glucose tolerance: does it matter for prevention and treatment of type 2 diabetes?

K Faerch, K Borch-Johnsen, J J Holst, A Vaag

2 registry-linked trialsOpen access · bronzeAbstract read
PubMed Publisher
In one paragraph

Article in Diabetologia, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 2 registered trials, which are not on this map. Cited by 120 papers, 6 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
120citing papers in PubMed, 6 pooled it
14.7field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT03004612 phase4completedstarted 2016, after this paper: background citation

Effect of Linagliptin + Metformin vs Metformin Alone on the Role of Pancreatic Islet Function, Insulin Resistance and Markers of Cardiovascular Risk in Patients With Prediabetes: Randomized Clinical Trial

Ran2016Enrolled144Registered outcomes5Posted comparisons0ConditionsInsulin Resistance, Prediabetic StateArmsLinagliptin + metformin, Metformin
Open the trial in the graph
NCT04134650 phase3unknown statusstarted 2019, after this paper: background citation

Effect of Low Dose Combination of Linagliptin and Metformin to Improve Pancreatic Beta Cell Function, Insulin Resistance and Cardiovascular Function in Patients With Prediabetes and Overweight/Obesity: Randomizer Clinical Trial

Ran2019Enrolled34Registered outcomes3Posted comparisons0ConditionsInsulin Resistance, Prediabetic StateArmsLinagliptin + metformin, Metformin
Open the trial in the graph
3 · Its place in the literature

Who cites it

120 citing papers in PubMed, 6 syntheses or guidelines pooled it, 245 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Pooled it
  7. Nutrients · 2021
    Trial
  8. Trial
  9. Trial
  10. Trial
  11. Trial
  12. Trial
  13. Chromium effects on glucose tolerance and insulin sensitivity in persons at risk for diabetes mellitus.Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists
    Trial
  14. Article
  15. Article
  16. Article
  17. Not all prediabetes is the same in its effect for bone health.The Korean journal of internal medicine · 2026
    Article
  18. Article
  19. Article
  20. Review

60 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 2 institutions in 1 country.

K FaerchSteno Diabetes Center, Niels Steensens Vej 2, 2820, Gentofte, Denmark. krif@steno.dk
K Borch-Johnsen
J J Holst
A Vaag
Steno Diabetes Center · DKUniversity of Copenhagen · DK

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Prior to the development of type 2 diabetes, glucose levels increase into the prediabetic states of isolated impaired fasting glycaemia (i-IFG), isolated impaired glucose tolerance (i-IGT), or combined IFG/IGT. A better understanding of the aetiology and pathophysiology of the prediabetic states might give a basis for the development of individualised prevention and treatment strategies for type 2 diabetes. Several studies have examined mechanisms and potential aetiological factors leading to the development of the different prediabetic states. The pathophysiology of i-IFG seems to include the following key defects: reduced hepatic insulin sensitivity, stationary beta cell dysfunction and/or chronic low beta cell mass, altered glucagon-like peptide-1 secretion and inappropriately elevated glucagon secretion. Conversely, the prediabetic state i-IGT is characterised by reduced peripheral insulin sensitivity, near-normal hepatic insulin sensitivity, progressive loss of beta cell function, reduced secretion of glucose-dependent insulinotropic polypeptide and inappropriately elevated glucagon secretion. Individuals developing combined IFG/IGT exhibit severe defects in both peripheral and hepatic insulin sensitivity as well as a progressive loss of beta cell function. The aetiologies of i-IFG and i-IGT also seem to differ, with i-IFG being predominantly related to genetic factors, smoking and male sex, while i-IGT is predominantly related to physical inactivity, unhealthy diet and short stature. Since the transition from the prediabetic states to overt type 2 diabetes is characterised by a non-reversible vicious cycle that includes severe deleterious effects on glucose metabolism, there are good reasons to use the well-established aetiological and pathophysiological differences in i-IFG, i-IGT and IFG/IGT to design individualised preventive strategies.

Indexed as

Blood GlucoseDiabetes Mellitus, Type 2ExerciseFastingFemaleGlucose IntoleranceGlycated HemoglobinHeart RateHumansInsulinJoggingMaleMiddle AgedObesityOverweightPrediabetic StateBlood GlucoseGlycated HemoglobinInsulin

Identifiers

PMID19590846
OpenAlexW2130756579

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.